Paxman Coolers Limited et al., 2017-04-17: 510(k) clearance of the Paxman Scalp Cooler with the DigniCap de novo as predicate. The indication is identical, and the summary reports a clinical study achieving less than 50% hair loss compared with no scalp cooling.
The Paxman Scalp Cooler is indicated to reduce the likelihood of chemotherapy-induced alopecia (CIA) in women with breast cancer.
Section 5, Indications for Use (PDF p.2)
Paxman Coolers Limited et al., 2017-04-17: 510(k) clearance of the Paxman Scalp Cooler with the DigniCap de novo as predicate. The indication is identical, and the summary reports a clinical study achieving less than 50% hair loss compared with no scalp cooling. openFDA gives the decision date as 2017-04-17 and the decision as 'Substantially Equivalent'. Predicate section names DEN150010 as the comparison device and states 'The subject device does not raise any new issues of safety or effectiveness'. Federal record; no funder or conflict issue. Study type: regulatory record.
